Physician profile
Diya Mohammad
NPI 1427339738
$8,511.54
in general payments reported to CMS, 2019-2025
25 companies · $4,794 in 2025
The $4,794 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $797 · 2020: $375 · 2021: $116 · 2022: $165 · 2023: $1,863 · 2024: $402 · 2025: $4,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,048 · Education: $2,662 · Food and Beverage: $1,149 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,048.02 |
| Education | $2,661.94 |
| Food and Beverage | $1,149.33 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,073.97 | 2023-2025 | Da Vinci Surgical System |
| Pulmonx Corporation | $942.93 | 2019-2020 | |
| Glaxosmithkline, LLC. | $202.27 | 2022-2024 | Nucala, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $171.62 | 2019-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $161.94 | 2023-2024 | |
| Abiomed | $130.16 | 2023 | Impella |
| Edwards Lifesciences Corporation | $96.84 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2020-2024 | Breztri, Tezspire |
| United Therapeutics Corporation | $62.68 | 2022-2024 | Tyvaso |
| Insmed, INC. | $49.80 | 2022-2023 | Arikayce |
| Genzyme Corporation | $42.44 | 2023 | |
| Merck Sharp & Dohme LLC | $40.93 | 2020-2024 | Winrevair |
| Baxter Healthcare | $39.47 | 2023 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Actelion Pharmaceuticals US, INC. | $32.89 | 2019-2023 | Opsumit, Uptravi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $32.53 | 2020-2022 | |
| Amgen INC. | $20.28 | 2022 | |
| Advanced Respiratory, INC | $20.08 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.50 | 2025 | |
| Ethicon INC. | $19.09 | 2021 | |
| Harmony Biosciences LLC | $18.22 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.44 | 2023 | Glassia |
| Electromed, INC. | $17.24 | 2019 | |
| Genentech USA, INC. | $16.67 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diya Mohammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.